UPB earnings date and last-quarter result: last quarter miss, P/E -2.26. Updated 2026-07-23.
Upstream Bio (UPB) Research Hub
Upstream Bio (UPB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.75 USD (+0.36%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.26, market cap 0.35B. This hub links to the full technical, earnings and options research available for UPB.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.75 USD (+0.36%) |
| 52-week range | 2.7 USD – 8 USD |
| Trend regime | Range |
| 14-day RSI | 15.9 (Oversold) |
| Trailing P/E | -2.26 |
| Market cap | 0.35B |
| Dividend yield | 0.00% |
Available research for UPB
Covered Call on UPB: how it works, illustrative setup around the real 2.75 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on UPB: how it works, illustrative setup around the real 2.75 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on UPB: how it works, illustrative setup around the real 2.75 USD price, max profit/loss, breakeven and when to use it. Educational.
UPB technical analysis: range, last 2.75 USD, RSI 15.9, 52w range 2.7 USD–8 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is UPB in?
Upstream Bio (UPB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is UPB in an uptrend or downtrend?
As of 2026-10-26, UPB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is UPB's trailing P/E ratio?
UPB's trailing P/E is -2.26, with a market cap of 0.35B. See the earnings research page for full valuation detail.